Aktive Positionen von Kristen M. Lorentz
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Corporate Officer/Principal | 31.12.2012 | - |
| Gründer | - | - | |
| Technik-/Wissenschafts-/F&E-Leiter | 31.12.2012 | - |
Karriereverlauf von Kristen M. Lorentz
Ehemalige bekannte Positionen von Kristen M. Lorentz
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Gründer | 01.01.2015 | - |
Statistik
International
| Schweiz | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Health Services |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Kristen M. Lorentz
- Erfahrung
